Pricing Log in Create free account

Hyperion DeFi, Inc. (HYPD) vs Kalaris Therapeutics Inc. (KLRS)

Hyperion DeFi, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. Hyperion DeFi, Inc. and Kalaris Therapeutics Inc. are of similar size ($49.0M and $47.8M). Kalaris Therapeutics Inc. has the higher net margin (0.00% vs −1,224.5%) and the lower return on invested capital (0.00% vs 2.73%). Across the 15 metrics below, Kalaris Therapeutics Inc. leads on 8 and Hyperion DeFi, Inc. on 7.

Valuation

Metric HYPD KLRS Biotechnology median
P/E n/m n/m 8.50
P/S 28.74 n/m 9.71
P/B 0.39 0.83 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 7.98 0.55 0.64
EV/Sales 27.88 n/m 9.21
Earnings yield (217.96%) (101.00%) (33.15%)
Free cash flow yield (191.71%) (85.89%) (25.50%)

Profitability

Metric HYPD KLRS Biotechnology median
Gross margin 78.35% 0.00% 65.16%
Operating margin 314.32% 0.00% 0.00%
Net margin (1,224.53%) 0.00% 0.00%
Free cash flow margin (5,509.35%) 0.00% 0.00%
Return on equity (24.63%) (79.91%) (56.36%)
Return on assets (20.32%) (46.02%) (48.04%)
Return on invested capital 2.73% 0.00% 0.00%

Growth

Metric HYPD KLRS Biotechnology median
Revenue growth (TTM) 1,990.60% — 6.02%
EPS growth (last fiscal year) 84.28% 94.50% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HYPD KLRS Biotechnology median
Debt to equity 0.08 0.00 0.00
Current ratio 2.34 10.98 4.72
Net debt to EBITDA (0.03) 2.54 0.96

Dividend

Metric HYPD KLRS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric HYPD KLRS Biotechnology median
Market cap 48.95m 47.83m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack